AbbVie Reports Higher Remission Rates in Phase 2a Crohn’s Study
AbbVie said investigational therapy ABBV-466 achieved higher endoscopic remission rates than either component therapy alone in patients with moderate to severe Crohn’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.